Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Molecules ; 26(6)2021 Mar 17.
Article in English | MEDLINE | ID: mdl-33802960

ABSTRACT

Risperidone (RSP) is an atypical antipsychotic drug used in treating schizophrenia, behavioral, and psychological symptoms of dementia and irritability associated with autism. The drug substance is practically insoluble in water and exhibits high lipophilicity. It also presents incompatibilities with pharmaceutical excipients such as magnesium stearate, lactose, and cellulose microcrystalline. RSP encapsulation by randomly methylated ß-cyclodextrin (RM-ß-CD) was performed in order to enhance drug solubility and stability and improve its biopharmaceutical profile. The inclusion complex formation was evaluated using thermal methods, powder X-ray diffractometry (PXRD), universal-attenuated total reflectance Fourier transform infrared (UATR-FTIR), UV spectroscopy, and saturation solubility studies. The 1:1 stoichiometry ratio and the apparent stability constant of the inclusion complex were determined by means of the phase solubility method. The compatibility between the supramolecular adduct and pharmaceutical excipients starch, anhydrous lactose, magnesium stearate, and cellulose microcrystalline was studied employing thermoanalytical tools (TG-thermogravimetry/DTG-derivative thermogravimetry/HF-heat flow) and spectroscopic techniques (UATR-FTIR, PXRD). The compatibility study reveals that there are no interactions between the supramolecular adduct with starch, magnesium stearate, and cellulose microcrystalline, while incompatibility with anhydrous lactose is observed even under ambient conditions. The supramolecular adduct of RSP with RM-ß-CD represents a valuable candidate for further research in developing new formulations with enhanced bioavailability and stability, and the results of this study allow a pertinent selection of three excipients that can be incorporated in solid dosage forms.


Subject(s)
Drug Compounding/methods , Excipients/chemistry , Risperidone/pharmacology , beta-Cyclodextrins/chemistry , Models, Molecular , Molecular Docking Simulation , Solubility , Spectroscopy, Fourier Transform Infrared , Temperature , Thermogravimetry , X-Ray Diffraction
2.
Molecules ; 25(23)2020 Dec 03.
Article in English | MEDLINE | ID: mdl-33287127

ABSTRACT

Risperidone (RSP) is an atypical antipsychotic drug which acts as a potent antagonist of serotonin-2 (5TH2) and dopamine-2 (D2) receptors in the brain; it is used to treat schizophrenia, behavioral and psychological symptoms of dementia and irritability associated with autism. It is a poorly water soluble benzoxazole derivative with high lipophilicity. Supramolecular adducts between drug substance and two methylated ß-cyclodextrins, namely heptakis(2,6-di-O-methyl)-ß-cyclodextrin (DM-ß-CD) and heptakis(2,3,6-tri-O-methyl)-ß-cyclodextrin (TM-ß-CD) were obtained in order to enhance RSP solubility and improve its biopharmaceutical profile. The inclusion complexes were evaluated by means of thermoanalytical methods (TG-thermogravimetry/DTG-derivative thermogravimetry/HF-heat flow), powder X-ray diffractometry (PXRD), universal-attenuated total reflectance Fourier transform infrared (UATR-FTIR), UV spectroscopy and saturation solubility studies. Job's method was employed for the determination of the stoichiometry of the inclusion complexes, which was found to be 2:1 for both guest-host systems. Molecular modeling studies were carried out for an in-depth characterization of the interaction between drug substance and cyclodextrins (CDs). The physicochemical properties of the supramolecular systems differ from those of RSP, demonstrating the inclusion complex formation between drug and CDs. The RSP solubility was enhanced as a result of drug encapsulation in the CDs cavity, the higher increase being obtained with DM-ß-CD as host; the guest-host system RSP/DM-ß-CD can thus be a starting point for further research in developing new formulations containing RSP, with enhanced bioavailability.


Subject(s)
Risperidone/chemistry , beta-Cyclodextrins/chemistry , Calorimetry, Differential Scanning/methods , Cyclodextrins/chemistry , Drug Compounding/methods , Models, Molecular , Solubility , Spectroscopy, Fourier Transform Infrared , Thermogravimetry/methods , X-Ray Diffraction/methods
3.
Polymers (Basel) ; 12(7)2020 Jul 10.
Article in English | MEDLINE | ID: mdl-32664336

ABSTRACT

Ester polyurethane (PU) foam waste was reacted at atmospheric pressure in an autoclave and using microwaves with diethylene glycol (DEG) at different PU/DEG ratios in the presence of diethanolamine as a catalyst to find the glycolysis conditions that allow for the improved recovery of the PU foam waste and enable the recycling of the whole glycolysis product in foam formulations suitable for industrial application. The recycled polyol was characterized by dynamic viscosity, hydroxyl number, water content, and density, while thermal stability was assessed using thermogravimetric analysis. In the PU foam formulation, 1% and 5% of the glycolyzed material was reused. The relationship between the reuse level of the recycled polyol and the physical properties of the foam was thoroughly investigated. It was observed that both hardness and air flow decreased with increasing recycled polyol content, particularly for the polyester type foam, while tensile strength and compression strength increased. Depending on the amount of recycled polyol and catalyst used, polyether-based foams could be obtained with a low air permeability, needed in special applications as sealed foams, or with higher air permeability desirable for comfort PU foams. The results open the way for further optimization studies of industrial polyurethane foam formulations using a glycolysis process without any separation stage.

SELECTION OF CITATIONS
SEARCH DETAIL
...